Stacking and cycling are the strategy layer of strength peptides — how individual compounds combine into protocols, how protocols sequence across cycles, and how to avoid the mistakes that turn a reasonable plan into wasted time and money.
This pillar covers the most-reported stacks, cycle-length frameworks by peptide class, off-cycle strategies, and the stacking mistakes that derail more protocols than vendor quality.
The stack vs the cycle distinction
These are different things:
| Concept | What it means |
|---|---|
| Stack | Multiple peptides run at the same time within a single cycle |
| Cycle | A defined on-period for a peptide or stack, followed by an off-period |
| Protocol | The full plan: stack composition, doses, cycle length, off-period, monitoring |
You can run a single peptide in a cycle (no stack). You cannot really run a "permanent stack" without the cycle component — what you'd have is just continuous use, which has its own concerns.
The most-reported stacks
Recovery stack: BPC-157 + TB-500
The most popular peptide stack in the strength community. Mechanism complementary, not redundant:
| Compound | Action | Cadence |
|---|---|---|
| BPC-157 | Local angiogenesis, growth-factor upregulation | Daily SubQ |
| TB-500 | Systemic actin reorganization, cell migration | Twice-weekly loading, then every 1–2 weeks |
Cycle: 6–8 weeks. Best for: chronic tendinopathy, multiple overlapping injuries, hard training blocks.
For full breakdown: recovery stack: BPC + TB-500.
GH-axis stack: Ipamorelin + CJC-1295 (no DAC)
The cleanest GH-axis stack — synergistic GH pulses without significant cortisol or prolactin elevation:
| Compound | Action | Cadence |
|---|---|---|
| Ipamorelin | Ghrelin receptor → GH release | 100–300 mcg, 1–3x daily |
| CJC-1295 (no DAC) | GHRH receptor → amplifies GH pulse | 100–300 mcg, paired with Ipa |
Cycle: 12–16 weeks. Best for: body composition, sleep quality, GH-axis support in 30s+.
For full breakdown: GH stack: Ipa + CJC.
Fat-loss stack: GH secretagogues + MOTS-c
For users in a cutting phase who want metabolic support beyond diet:
| Compound | Action | Cadence |
|---|---|---|
| Ipamorelin + CJC-1295 (no DAC) | Modest GH/IGF-1 elevation, fat oxidation | Pre-bed and pre-training |
| MOTS-c | AMPK activation, insulin sensitivity | 2–3x weekly |
Cycle: 8–12 weeks. Best for: athletes in defined fat-loss phases.
For full breakdown: fat-loss stack.
Anti-aging stack: Sermorelin + GHK-Cu (topical) + BPC-157 (low-dose oral)
A gentle, continuous-leaning stack:
| Compound | Action | Cadence |
|---|---|---|
| Sermorelin | Natural-pulse GH support | 200 mcg pre-bed |
| GHK-Cu (topical) | Skin remodeling, anti-inflammatory | Daily |
| BPC-157 (low-dose oral) | Gut and systemic anti-inflammatory | 250 mcg/day |
Cycle: longer cycles (16+ weeks) or near-continuous with breaks. Best for: middle-aged users prioritizing recovery, sleep, and tissue maintenance.
For full breakdown: anti-aging stack.
Anabolic stack: IGF-1 LR3 + GH secretagogues
The most aggressive strength stack — combines direct anabolic signaling (IGF-1 LR3) with GH-axis support to maintain natural rhythms:
| Compound | Action | Cadence |
|---|---|---|
| Ipamorelin + CJC-1295 (no DAC) | Pituitary GH release | Standard |
| IGF-1 LR3 | Direct IGF-1 receptor activation | 20–40 mcg/day |
Cycle: 4–6 weeks (limited by IGF-1 LR3). Best for: experienced users, focused training blocks.
The risk profile of this stack is the sharpest in the category. Cancer-axis caveats, hypoglycemia management, and tighter monitoring all matter here.
Cycle length frameworks
Cycle length isn't arbitrary — it's tied to how each peptide class behaves:
| Peptide class | Typical cycle | Off-period | Reasoning |
|---|---|---|---|
| BPC-157, TB-500 | 4–8 weeks | 4–8 weeks | Match recovery goal; avoid continuous angiogenic signaling |
| Short-acting GH secretagogues | 12–16 weeks | 4–8 weeks | GH-axis effects need 8+ weeks to express |
| Long-acting GH secretagogues (CJC DAC) | 12 weeks | 8+ weeks | Higher receptor desensitization concern |
| MK-677 | 8–12 weeks | 4–8 weeks | Insulin-sensitivity drift on long runs |
| IGF-1 LR3 | 4–6 weeks | 4–8 weeks | Receptor desensitization + cancer-axis caveats |
| MOTS-c | 8–12 weeks | 4–8 weeks | Match metabolic adaptation timeline |
| GHK-Cu (topical) | Continuous OK | — | Cosmetic-grade, decades of safety |
| GHK-Cu (injection) | 6–12 weeks | 4 weeks | Less data on chronic injectable use |
| Tesamorelin | Per indication | Per indication | FDA-approved for HIV-LD; otherwise cycle |
For more detail by peptide, see cycle length by peptide.
Off-cycle strategies
The off period matters as much as the on. During off-cycles:
- Don't substitute another peptide just to "stay on something." That's continuous use with extra steps.
- Bloodwork at end-of-cycle is more useful than mid-cycle — it shows your post-cycle baseline
- Document subjective effects during off-cycle — this is when you find out what the peptide was actually doing
- Plan training and life stress to fit the off-period — don't try to peak performance during a planned off
For more, see off-cycle strategies.
Stacking mistakes to avoid
The mistakes that produce the most wasted cycles:
| Mistake | Why it derails |
|---|---|
| Starting with a stack | Can't isolate which peptide is doing what (or causing what) |
| Stacking peptides with overlapping mechanisms | E.g., GHRP-2 + Ipamorelin both hit the ghrelin receptor — diminishing returns |
| Stacking IGF-1 LR3 with synthetic HGH | Doubles up on the same pathway with compounded side-effect risk |
| Running multiple cycles back-to-back | Cumulative side effects without recovery windows |
| Adding a peptide mid-cycle | Confounds attribution of any effect or side effect |
| Stacking peptides without baseline labs | No way to detect drift in glucose, lipids, etc. |
| Stacking based on internet protocols | What works for someone else's body may not be optimal for yours |
For full coverage: stacking mistakes to avoid.
Building your own protocol
Reasonable order of operations for a first stack:
- Define the goal. "Recovery from stubborn Achilles tendinopathy" is a goal. "Get bigger" is not — be specific.
- Pick the primary peptide for that goal. BPC-157 for recovery, Ipa+CJC for GH-axis support, etc.
- Run that single peptide for a full cycle. Establish baseline response and identify any side effects.
- End-of-cycle reassessment. Did it move the needle? Were there side effects? Should you continue or pivot?
- Subsequent cycles can stack — add a second peptide with a complementary mechanism.
- Don't go past 3 peptides in a single stack without strong reason — confounding gets unmanageable.
- Document everything. Subjective effects, lab work, dose, vendor, batch.
A note on PCT
PCT — Post-Cycle Therapy — is a concept from anabolic-steroid protocols where exogenous hormones suppress endogenous production and post-cycle drugs help restart it. Most strength peptides don't need PCT:
- BPC-157, TB-500: no PCT needed; no hormonal suppression
- Short-acting GH secretagogues: no PCT needed; pituitary recovers rapidly
- IGF-1 LR3: brief GH-axis suppression that recovers on its own
- MOTS-c, GHK-Cu: no PCT needed
- Long-acting GH secretagogues (CJC DAC, MK-677): mild downregulation; off-period is the recovery, no PCT compounds needed
Where PCT does fit: stacks that include synthetic HGH or that suppress the HPTA. These are not the protocols this site focuses on. See post-cycle peptide protocols.